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Abstract
Background: Repeated exposure to methamphetamine (METH) can cause not only neurotoxicity but also
addiction. Behavioral sensitization is widely used as an animal model for the study of drug addiction. We previously
reported that the μ-opioid receptor knockout mice were resistant to METH-induced behavioral sensitization but the
mechanism is unknown.
Methods: The present study determined whether resistance of the μ-opioid receptor (μ-OR) knockout mice to
behavioral sensitization is due to differential expression of the stimulatory G protein a subunit (Gas) or regulators
of G-protein signaling (RGS) coupled to the dopamine D1 receptor. Mice received daily intraperitoneal injections of
saline or METH (10 mg/kg) for 7 consecutive days to induce sensitization. On day 11(following 4 abstinent days),
mice were either given a test dose of METH (10 mg/kg) for behavioral testing or sacrificed for neurochemical
assays without additional METH treatment.
Results: METH challenge-induced stereotyped behaviors were significantly reduced in the μ-opioid receptor
knockout mice when compared with those in wild-type mice. Neurochemical assays indicated that there is a
decrease in dopamine D1 receptor ligand binding and an increase in the expression of RGS4 mRNA in the striatum
of METH-treated μ-opioid receptor knockout mice but not of METH-treated wild-type mice. METH treatment had
no effect on the expression of Gas and RGS2 mRNA in the striatum of either strain of mice.
Conclusions: These results indicate that down-regulation of the expression of the dopamine D1 receptor and up-
regulation of RGS4 mRNA expression in the striatum may contribute to the reduced response to METH-induced
stereotypy behavior in μ-opioid receptor knockout mice. Our results highlight the interactions of the μ-opioid receptor
system to METH-induced behavioral responses by influencing the expression of RGS of dopamine D1 receptors.
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Background
Methamphetamine (METH) is a highly abused CNS sti-
mulant with high reward properties that leads to com-
pulsive drug seeking behavior [1,2]. The mechanism of
the additive properties to METH remains to be deter-
mined. Repeated administration of METH results in
behavioral sensitization characterized by persistent
hyperlocomotor activity and stereotyped behaviors [3,4].
Animals remain sensitized for many weeks, suggesting
that the development of sensitization involves long-last-
ing neuronal adaptations [5]. The neural alterations
underlying behavioral sensitization are also thought to
contribute to mimic changes associated with the com-
pulsive drug seeking behavior. Thus, behavioral sensiti-
zation is widely used as an animal model for the study
of drug addiction [5-8] and it is extremely important to
find therapeutic agents for behavioral sensitization to
psychostimulants.
The dopamine system is generally considered a main
target for amphetamines to stimulate locomotor activity
and stereotyped behaviors. The nigrostriatal dopaminer-
gic pathway consists of dopaminergic neurons of the
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any medium, provided the original work is properly cited.substantia nigra that innervate the striatum [9] that is
intimately linked to the stereotyped behaviors produced
by psychomotor stimulants [10]. It is well known that
an increase in dopaminergic activity in the central ner-
vous system (CNS) plays a central role in induction and
expression of behavioral sensitization by psychomotor
stimulants. For example it is known that activation of
dopamine receptors is required for the expression of
behavioral sensitization by METH [11]. METH stimu-
lates the release of dopamine from dopaminergic neu-
rons and activates dopamine receptors [12]. Dopamine
receptors as members of the G protein-coupled receptor
(GPCR) superfamily elicit a variety of cellular and beha-
vioral responses through various signaling pathways to
induce behavioral effects [13]. Regulators of G-protein
signaling (RGS) proteins negatively regulate GPCR sig-
n a l i n g ,c h a n g e si nR G Sp r o t e i nl e v e l si nt h eb r a i na r e
thought to modulate the intensity and duration of signal-
ing of cognate receptors [14]. The expression of several
RGS proteins in the brain is rapidly altered in response to
psychostimulants [15]. In addition there is growing
evidence that exposure to amphetamine-like stimulants
influences the expression of dopamine receptors, G-pro-
teins and RGS in neurons that may contribute to stimu-
lant-mediated behavioral responses [16]. Chronic
administration of dopamine D1 agonist SKF 38393 results
in enhanced behavioral responses to subsequent adminis-
tration of a variety of dopamine agonists [17,18]. Others
have found that stereotypic behavior in response to
amphetamine administration is associated with increased
expression of dopamine D1 receptors [19] and hypersensi-
tivity of adenylate cyclase to dopamine stimulation which
is blocked by the dopamine D1 antagonist SCH 23390
[20].
It is also clear that there are extensive anatomical and
functional interactions between the dopaminergic sys-
tem and other neuronal pathways. For example both
the opioidergic and glutamatergic systems contribute to
the development and maintenance of behavioral sensiti-
zation to METH [21]. Endogenous opioid systems have
been found to play important roles in reward, positive
reinforcement, and additive effects on drugs of abuse
[22-24]. The endogenous opioid systems consist of a
variety of endogenous opioid peptides and receptors. At
least three opioid receptor subtypes (δ, μ,a n d)a r e
currently recognized [25]. Enkephalins have high affinity
for μ-a n dδ- opioid receptors whereas dynorphins have
high affinity for -opioid receptors. It has been reported
that amphetamines induce an increase in expression of
the opioid peptide enkephalin precursor preproenkepha-
lin mRNA in rodent striatum [26]. No behavioral sensi-
tization to amphetamine was detected in the enkephalin
knockout mice [27]. We also reported that μ-opioid
receptor (μ-OR) knockout mice were less sensitive to
the development of behavioral sensitization to METH
[28]. However, it remains to be determined how μ-OR
contribute to METH-induced behavioral responses. The
present study examined whether METH exposure
causes differential changes in the expression of stimula-
tory Ga (Gas; subunit coupled to dopamine D1 recep-
tors) or RGS associated with dopamine D1 receptors in
the CNS that may contribute to the resistance to
METH-induced behavioral sensitization in μ-OR knock-
out mice.
Materials and methods
Animals and drug treatments
The μ-OR knockout mice were originally developed by
Loh et al. [29] on a C57/BL6 and 129/Ola hybrid genetic
background. Our colony was maintained as heterozygotes
by brother sister mating in the Laboratory Animal Facility
of the University of Mississippi Medical Center (UMMC).
All procedures were approved by Institutional Animal
Care and Use Committee of the UMMC, and performed
in compliance with the NIH Guide for the Care and Use
of Laboratory Animals. Adult male wild-type and μ-OR
knockout mice were used in this study. μ-OR knockout
and wild-type mice (n = 12 for each genotype) were given
METH (10 mg/kg, i.p.) once a day for 7 consecutive days
to induce sensitization in order to investigate METH-
evoked behavioral response. This dose was chosen on the
basis of previous studies indicating that it was the dose
that induced stereotyped behavioral sensitization to sub-
chronic administration of METH in mice [28,30]. On day
11, after a 4 day drug washout period, the sensitized mice
were challenged with a i.p. injection of METH (10 mg/kg).
Stereotyped behaviors were monitored for 30 min before
and for 5 hrs after the injection to evaluate the behavioral
responses.
The behavior of mice was monitored in a Plexiglas
® box
equipped with a CCD camera and recorded on video tape,
which was subsequently analyzed by a trained observer.
The intensity of stereotyped activity was scored on 4-point
scale (0 - normal behavior, 1 - periodic sniffing, 2 - contin-
uous sniffing, 3 - continuous sniffing, periodic licking or
gnawing, 4 - continuous licking or gnawing) as described
by Costall and colleagues [31].
Parallel experiments were performed in another group
of wild-type and μ-OR knockout mice to assess changes in
the expression of dopamine receptors and mRNA in the
brain. These animals were sensitized using the same 7 day
exposure to METH or vehicle. After a 4 day drug-washout
period, the animals were decapitated and the brains col-
lected and frozen in liquid nitrogen. Coronal sections (14-
20 mm thick) were cut using a cryostat (Tissue-Tek, cyro
2000) at -20°C, thaw-mounted on gelatin-coated slides
and stored at -80°C for autoradiography and in situ hybri-
dization analysis.
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Dopamine D1 receptor levels were measured using radi-
olabeled ligand binding and autoradiography as previously
described by Qian et al. [32]. Briefly, brain sections were
pre-incubated at 4°C for 30 min in a 50 mM Tris-HCI buf-
fer (pH 7.4) containing 120 mM NaCl, 5 mM KCl, 2 mM
CaCl2,a n d1m MM g C l 2, and then incubated for 60 min
with 1.6 nM of the labeled dopamine D1 receptor antago-
nist [
3H]SCH23390 at room temperature. Other sections
were incubated with 30 μM of the dopamine D1 receptor
ligand (±)SKF38393 [33] to control for nonspecific bind-
ing. The labeled brain sections as well as a set of [
3H]-
impregnated plastic standards ([
3H]Microscale, Amersham
Life Science) were placed on Kodak BioMax MS film for 3
weeks (-80°C). The films were developed, and then ana-
lyzed using a scanning densitometer and Image Quant 3.3
program (Molecular Dynamics; Sunnyvale, CA).
In Situ Hybridization
The expression of Gas, RGS2, and RGS4 mRNAs in the
brain were determined using in situ hybridization. The
focus of the present experiment was to examine changes
in the expression of Gas, RGS2, and RGS4 in the striatum
of the mouse brain. We and others have used in situ hybri-
dization techniques [34-36] to successfully study gene
expression for a wide variety of gene products. The techni-
que relies on the specificity of the probe. Oligonucleotide
probes complementary to mRNAs encoding mouse Gas
(5’-GCAAAGCAGCGCCTGCCTGCCCGTCTGCCTG
CCGCCGCC-3’) [34], RGS2 (5’-GGGCTCCGTGGT
GATCTGTGGCTTTTTACATAAG-3’), and RGS4 (5’-
GCTGG AAGGATTGGTCAGGTCAAGATAGAATC-
GAG-3’) [35] were 3’ end labeled with [
35S]dATP using
terminal deoxynucleotidyltransferase (PerkinElmer Life
Sciences, Shelton, CT) and in situ hybridization was per-
formed as described earlier [36]. The probes used were
identical to those described by Tervonen et al. [35] who
verified that they specifically bound to RGS2 and RGS4
and Przewlocka et al. [34] who tested the Gas probe. We
also BLASTED the sequence of the probes against all of
the sequences in GENBANK and found that they exhib-
ited a 100% match to the intended target. Only the RGS4
probe exhibited any significant homology (17 of 35 bp) to
another target, i.e. the presenilin-2 gene. However, given
the limited numbers of complementary base pairs, it is
highly unlikely that the RGS4 would bind to this target at
the hybridization temperature used of 38°C. Moreover, we
also performed appropriate control experiment to exclude
non-specific binding. The labeled slides were exposed to
Kodak BioMax MR films for 5 days for Gaso r1 1w e e k s
for RGS2 and RGS4, and the films were developed and
fixed. The quantification of the autoradiogram was per-
formed using the Image Quant software (Molecular
Dynamics, Sunnyvale, CA).
Statistical Analysis
Data are expressed as mean values ± SEM. The signifi-
cance of differences in mean values was analyzed using
a t test (stereotyped behaviors) or a two-way ANOVA
followed by a Student-Newman-Keuls post hoc test. A
P < 0.05 was considered to be significant.
Results
METH-evoked stereotyped behaviors in METH-sensitized
wild-type and μ-OR knockout mice
Administration of METH in sensitized wild-type animals
produced stereotyped behaviors, characterized by con-
tinuous sniffing and licking that persisted for about
5h o u r s .I nt h eμ-OR knockout mice the cumulative
score of stereotyped behaviors was significantly lower
than in the wild-type mice (Figure 1).
[
3H]SCH23390 binding in the striatum of METH-sensitized
wild-type and μ-OR knockout mice
Representative autoradiograms of [
3H]SCH23390 bind-
ing in the brain of wild-type and μ-OR knockout mice
are presented in Figure 2. High levels of [
3H]SCH23390
binding were seen in the striatum. Basal binding of [
3H]
SCH23390 in the striatum was not significantly different
between wild-type and μ-OR knockout mice treated
with saline. Repeated METH treatment had no signifi-
cant effect on D1 receptor binding in wild type mice. In
contrast, the binding of [
3H]SCH23390 was markedly
reduced in the μ-OR knockout in mice sensitized by
repeated exposure to METH.
Wild-type mice
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Figure 1 METH (10 mg/kg)-evoked stereotyped behaviors in
wild-type and μ-OR knockout mice that were exposed to
METH for 7 days. METH (10 mg/kg)-evoked stereotyped behaviors
in wild-type and μ-OR knockout mice that were exposed to METH
for 7 days. Mean values ± SEM are presented. Numbers in
parentheses represent the number of animals studied. * indicates a
significant difference (P < 0.05) from the corresponding value in
METH-sensitized wild-type mice.
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(Gas) mRNA in the striatum of METH-sensitized wild-type
and μ-OR knockout mice
Representative autoradiograms of in situ hybridization of
Gas mRNA in the brain of wild-type and μ-OR knockout
mice are presented in Figure 3. Gasm R N Ai sw i d e l y
expressed in most brain areas including striatum and cer-
ebral cortex. The expression of Gas in the striatum was
similar in both wild-type and μ-OR knockout animals
treated with saline. METH treatment did not alter the
Figure 2 Binding of dopamine D1 ligand [
3H]SCH23390 in the brains of METH-sensitized wild-type and μ-OR knockout mice. Binding of
dopamine D1 ligand [
3H]SCH23390 in the brains of METH-sensitized wild-type and μ-OR knockout mice. Both strains of mice were pretreated
with daily injections saline or METH (10 mg/kg) for 7 consecutive days. Mice were killed 4 days after the final injection and brain tissues were
taken for autoradiographic analysis of [
3H]SCH23390 binding. Representative autoradiograms of [
3H]SCH23390 binding are shown on the top.
Mean values ± SEM are presented. Numbers in parentheses represent the number of animals/brains studied. * indicates a significant difference (P
< 0.05) from METH-sensitized wild-type mice; # indicates a significant difference (P < 0.05) from saline-treated μ-OR knockout mice.
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or in μ-OR knockout mice.
The expression of RGS2 and RGS4 mRNAs in the striatum
of METH-sensitized wild-type and μ-OR knockout mice
Representative autoradiograms of in situ hybridization sig-
nals for RGS2 and RGS4 mRNAs in the brain of wild-type
and μ-OR knockout animals are presented in Figures 4
and 5, respectively. Both of RGS2 and RGS4 mRNAs were
highly expressed in the striatum. There was no significant
difference in the expression of RGS2 mRNA in the stria-
tum of μ-OR knockout or wild-type mice treated with sal-
ine or METH. Basal expression of RGS4 was also similar
in μ-OR knockout and wild-type mice treated with saline.
However, the expression of RGS4 mRNA in the striatum
increased in μ-OR knockout mice treated with METH but
Figure 3 The expression of Gas mRNA in the brains of METH-sensitized wild-type and μ-OR knockout mice. The expression of Gas
mRNA in the brains of METH-sensitized wild-type and μ-OR knockout mice. Animal treatments were the same as described in Fig. 2. Gas mRNA
levels in the brain sections were analyzed by in situ hybridization analysis. Representative autoradiograms of Gas mRNA expression in the brain
of mice are presented at the top of the figure. Mean values ± SEM are presented. Numbers in parentheses represent the number of animals/
brains studied.
Park et al. Journal of Biomedical Science 2011, 18:83
http://www.jbiomedsci.com/content/18/1/83
Page 5 of 10remained unchanged in wild-ty p em i c es e n s i t i z e dw i t h
METH.
Discussion
The CNS stimulant-METH induces behavioral sensitiza-
tion which is associated persistent hyperlocomotor activ-
ity and stereotyped behaviors. Behavior sensitization is a
widely used in rodents model for study of drug addiction
and drug seeking behaviors [5,37]. In the present study
we confirmed previous finding that μ-OR knockout mice
demonstrate significantly decreased behavioral sensitiza-
tion to METH as compared with wild-type mice. This
was associated with a significant reduction in dopamine
D1 receptor density in the striatum of approximately 30%
in μ- O Rk n o c k o u tm i c ew h e nc o m p a r e dt ow i l d - t y p e
mice exposed to METH. By way of contrast, METH had
Figure 4 The expression of RGS2 mRNA in the brains of METH-sensitized wild-type and μ-OR knockout mice. The expression of RGS2
mRNA in the brains of METH-sensitized wild-type and μ-OR knockout mice. Animal treatments and preparation of brain sections for analysis of
RGS2 mRNA levels were the same as described in Fig. 3. Representative autoradiograms of RGS2 mRNA expression in the brain of mice are
presented at the top of the figure. Mean values ± SEM are presented. Numbers in parentheses represent the number of animals/brains studied.
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tum of wild-type mice.
We also found that the expression of Gasm R N Aw a s
unaltered by METH exposure in wild type or knockout
mice, as was the expression of mRNA of the regulator
of G-protein signaling, RGS2. However, the expression
of RGS4 mRNA was significantly increased in the
striatum of METH treated μ-OR knockout mice as com-
pared to saline treated controls, whereas METH treat-
ment had no effect on RGS4 mRNA in wild-type
controls. These data suggest that in μ-OR knockout
mice dopamine D1 receptor function in the striatum
can be more readily down-regulated than in wild- type
mice after repeated METH exposure. This may, in part,
Figure 5 The expression of RGS4 mRNA in the brains of METH-sensitized wild-type and μ-OR knockout mice. The expression of RGS4
mRNA in the brains of METH-sensitized wild-type and μ-OR knockout mice. Animal treatments and preparation of brain sections for analysis of
RGS4 mRNA levels were the same as described in Fig. 3. Representative autoradiograms of RGS4 mRNA expression are shown at the top. Mean
values ± SEM are presented. Numbers in parentheses represent the number of animals/brains studied. * indicates a significant difference (P <
0.05) from METH-sensitized wild-type mice; # indicates a significant difference (P < 0.05) from saline-treated μ-OR knockout mice.
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after METH treatment of μ-OR knockout mice.
Dopamine is an important neurotransmitter in the
CNS where it plays essential roles in numerous physiolo-
gical, neuronal, and behavioral processes. One important
component of the pathways in the CNS is the nigrostria-
tal dopaminergic system, projecting from the substantia
nigra to the striatum (putamen and caudate nucleus) that
is known to be crucial for the induction of stereotyped
behaviors [10]. Previously, we and others have performed
dose response studies and found that 2.5 mg/kg METH
is sufficient to elicit a locomotor response [28,38] but
higher doses (10 mg/kg) are needed to induce behavioral
sensitization to METH [28,30]. Repeated stimulation of
dopamine receptors with agonists has been shown to
cause down-regulation in expression of these receptors
[39]. As an indirect dopamine receptor agonist, METH is
known to stimulate the release and inhibit reuptake of
dopamine from synaptic cleft [40], increasing extracellu-
lar dopamine levels and activating postsynaptic striatal
dopamine receptors. Thus, repeated METH exposure
lead to down regulation of the expression of dopamine
receptors in the striatum. In other studies, we found that
METH (10 mg/kg) was associated with decreased tyro-
sine hydroxylase (the rate limiting enzyme of dopamine
synthesis) in wild-type mice but not in the μ-OR knock-
out mice. These results along with our present findings
indicate that the changes of dopaminergic system in mice
chronically exposed to METH is related to a decrease in
the expression of the enzyme involved in the synthesis of
dopamine and its actions on dopamine D1 receptors
rather than to the loss of dopaminergic neurons. None-
theless, these data demonstrate that the μ-opioid receptor
modulates the response of dopamine neurons to METH.
There are two types of dopamine receptors in the stria-
tum: D1 and D2. Striatonigral neurons largely express
dopamine D1 receptors whereas most striatopallidal neu-
rons express dopamine D2 receptors [41]. Although con-
current activation of dopamine D1 and D2 receptors is
thought to be required for the full induction of stereotyped
behaviors [11], activation of dopamine D1 receptors is pri-
marily responsible for the induction of dopamine-mediated
stereotypy [42]. Therefore, the down regulation of dopa-
mine D1 receptor we found in the striatum of METH-sen-
sitized μ-OR knockout mice compared with wild-type is
consistent with the view that this contributes to the less of
METH-induced stereotyped behaviors in this strain of
mice. Surprisingly, METH exposure in wild-type mice did
not down-regulate D1 dopamine receptors. Previously our
lab reported that quantitative autoradiographic analysis of
striatum and nucleus accumbens showed that METH
treatment leads to a decrease in dopamine D1 receptor
ligand binding in μ-OR knockout mice but not in wild-
type mice at low concentration (0.4 nM) of dopamine D1
receptor antagonist SCH 23390 [36]. This suggests that
interactions between opiodergic receptors/neurons and
neurons of the nigrostriatal pathway occur that stabilize
receptor density. These interactions between these path-
ways and the mechanisms involved deserve further study.
Chronic treatment (2-3 weeks) with dopamine D1
receptor antagonist SCH 23390 has been reported to
increase the expression of mRNA for preproenkephalin in
the rat striatum [43,44]. Recently, we found that there was
an increase in expression of preproenkephalin mRNA in
the nucleus accumbens and striatum in METH-sensitized
wild-type mice but not in μ-OR knockout mice [36]. Also,
METH induced hyperlocomotor activity at low doses and
stereotyped behaviors at high doses in wild-type mice [28]
but not in μ-OR knockout mice. These results indicate
that a decrease in striatal and nucleus accumbens D1
receptors in METH-sensitized μ-OR knockout mice is
associated with a decrease in the behavioral response in
these animals. The exact mechanism of how the μ-opioid
system modulates dopaminergic neurotransmission and
thus influences METH-produced behavioral responses is
unclear. Based on data in the literature, however, it can be
proposed that METH-induced changes in G protein sig-
naling and RGS proteins might play a role in the develop-
ment of behavioral sensitization to the drug.
Dopamine receptors are members of the GPCR family.
Stimulation of the dopamine D1 receptors activates ade-
nylyl cyclase via Gas, increasing intracellular cAMP that
activates cAMP-dependent protein kinase A and its
down-stream effectors [45]. There is evidence that G pro-
tein signaling may be disrupted in drug addiction and
neuropsychiatric disorders [46,47]. For example, post-
mortem brain studies have revealed increased levels of
Gas in bipolar disorder, a type of mood disorder with
unknown etiology as well as being inducible by CNS sti-
mulants [48]. Elevation of Gas levels is thought to
enhance signaling through the dopamine D1 receptor
and contribute to dopamine D1 receptor activation-
mediated behavioral responses [49]. Therefore, we exam-
ined the expression of Gasm R N Ai nt h es t r i a t u mo f
METH-sensitized mice. The results of the present study
indicate that the expression of Gasm R N Ai nt h es t r i a -
tum was not altered by repeated METH exposure in
either μ-OR knockout or wild-type mice.
Another possible effect of repeated METH exposure is
to alter the activity of the Ga protein. The primary regu-
lators of GTPase activity of Ga-subunits are RGS pro-
teins that rapidly terminate receptor-activated GaGTP
signaling by accelerating the hydrolysis of GTP to GDP
[50,51]. More than 30 mammalian RGS proteins have
been identified [50,52]. Gene expression studies demon-
strate that RGS2 and RGS4 are avidly expressed in cor-
tex, striatum, and several thalamic regions of the brain
[53,54]. The available evidence suggests that activation of
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coupled to RGS2 and RGS4 [55].
Amphetamine-like stimulants alters RGS mRNA
expression in the brain and triggers GPCR signaling
[56-58]. There are several lines of evidence that acute or
repeated treatment with amphetamine modulates drug-
induced behavioral and changes in gene and protein
expression of RGS4 in prefrontal cortex and dorsal stria-
tum [59-61]. RGS4 mRNA was decreased in the stria-
tum lasting from 1 to 6 hr after acute amphetamine
[62]. RGS4 may belong to the growing family of factors
regulating convergence of dopamine signaling in the
striatum [63].
In the present study, METH (10 mg/kg) exposure had
no influence on the expression of RGS2 mRNA in the
striatum of either μ-OR knockout or wild-type mice.
However, there was a higher expression of RGS4 mRNA
in the striatum of METH-sensitized μ-OR knockout
mice but not of wild-type mice. Increased expression of
RGS4 is consistent with a reduction in signaling via
dopamine D1 receptors in the striatum that may already
be reduced due to the decreased density of dopamine
D1 receptors in METH treated μ-OR knockout mice.
Down-regulation of dopamine D1 receptor binding in
combination with increased RGS4 mRNA levels is con-
sistent with diminished dopamine D1 receptor function
in METH-exposed μ- O Rk n o c k o u tm i c et h a tw o u l d
decrease the occurrence of behavioral sensitization.
Conclusions
In conclusion, the present study indicates that knockout
of μ-OR in mice reduces their sensitivity to METH-
induced stereotyped behaviors. Down-regulation of the
expression of the dopamine D1 receptor in combination
with up-regulation of the expression of RGS4 in the
striatum of METH-sensitized μ-OR knockout mice may
contributes to the resistance to the behavioral responses
to METH in this strain. The results suggest that the μ-
opioid system and RGS proteins might be targets for the
development of drugs that might reduce the reward
potential and compulsive drug seeking behavior in
METH abusers.
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